NINJ1 monoclonal antibody alleviates neuroinflammation and promotes functional recovery after spinal cord injury by suppressing pyroptosis-mediated DAMPs release - PubMed
3 days ago
- #Pyroptosis
- #Spinal Cord Injury
- #Neuroinflammation
- NINJ1 monoclonal antibody helps in reducing neuroinflammation and improving recovery after spinal cord injury by targeting pyroptosis-mediated DAMPs release.
- The study used a mouse contusion SCI model with different treatment groups, including NINJ1 mAb, showing significant improvement in motor function and reduced pathology.
- NINJ1 mAb treatment enhanced neuronal survival, suppressed pyroptosis executers like GSDMD, and decreased HMGB1 release.
- The treatment shifted microglial polarization from pro-inflammatory M1 to anti-inflammatory M2, reducing nuclear p-NF-κB p65 and increasing p-STAT3.
- In vitro studies confirmed NINJ1 mAb's direct protection of neurons and suppression of microglial M1 polarization and pro-inflammatory cytokine release.
- The findings suggest NINJ1 monoclonal antibody as a novel therapeutic strategy for spinal cord injury by inhibiting pyroptotic membrane rupture and modulating microglia.